Cargando…

SUN-053 Evaluation of a 52-Year-Old Transgender Man During the First Year of Testosterone Therapy - Biochemical Changes, Body Composition and Cardiovascular Aspects at the Ergometric Test: A Case Report

Introduction: Testosterone (T) therapy is able to promote biochemical, body composition and cardiovascular (CV) changes in transgender men (TM). However, existing data concerns TM between 18 and 50 years old. Objective: To describe the first year of T therapy in a 52 yo TM - biochemical changes, bod...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvares, Leonardo Azevedo Mobilia, Nakamoto, Fernanda Patti, Pimenta, Isabella Ferreira, Netto, Luiza Travassos da Rosa, Ramos, Henrique Afonso, boas, Roberta Frota Villas, Bueno, Thiago Limoli, Santos, Lívia Marcela, Silva, Frank Mobilia Alvares
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208401/
http://dx.doi.org/10.1210/jendso/bvaa046.903
_version_ 1783530836701741056
author Alvares, Leonardo Azevedo Mobilia
Nakamoto, Fernanda Patti
Pimenta, Isabella Ferreira
Netto, Luiza Travassos da Rosa
Ramos, Henrique Afonso
boas, Roberta Frota Villas
Bueno, Thiago Limoli
Santos, Lívia Marcela
Silva, Frank Mobilia Alvares
author_facet Alvares, Leonardo Azevedo Mobilia
Nakamoto, Fernanda Patti
Pimenta, Isabella Ferreira
Netto, Luiza Travassos da Rosa
Ramos, Henrique Afonso
boas, Roberta Frota Villas
Bueno, Thiago Limoli
Santos, Lívia Marcela
Silva, Frank Mobilia Alvares
author_sort Alvares, Leonardo Azevedo Mobilia
collection PubMed
description Introduction: Testosterone (T) therapy is able to promote biochemical, body composition and cardiovascular (CV) changes in transgender men (TM). However, existing data concerns TM between 18 and 50 years old. Objective: To describe the first year of T therapy in a 52 yo TM - biochemical changes, body composition and CV aspects during exercise. Methods: Medical record review was accessed as well as laboratorial and image exams performed during the first year of T use. Results: TM, 52 yo, in perimenopause, normal weight, without chronic diseases, no previous usage of T, initiated testosterone undecanoate 1.000mg. A second dose was given 6 weeks after the first one and then every 12 weeks. Lab exams were collected on the day before the next shot of T. By the third month of treatment, it has been noted the highest level of T (586 ng/dL). Initial hemoglobin (Hb) was 13.0 g/dL and hematocrit (Ht) 37.1%. After 7 months of treatment they reached their highest levels, 16.3 g/dL (23%) and 47,1% (27%). LDLc increased from 106 to 139 mg/dL (31%) by the seventh month. HDLc dropped from 73 to 60 (- 13 mg/dL) by the seventh month. Initial bone mineral density (BMD) was normal and increased 3.1% in lumbar spine (L1-L4) and 2.7% in femoral neck after 1 year. The muscle mass (MM) increased 10.9% in one year. The ergometric test (ET) at the beginning of treatment showed an increase in systolic blood pressure (SBP) of 38.4% (130 to 180 mmHg) during exertion and a decrease of 27.7% in the third minute of passive recovery; as well as an increase in Heart Rate (HR) of 73 bpm during exertion and a reduction of 72 bpm at third minute of rest. One year after the use of T, SBP increased by 61.5% (130 to 210 mmHg), with a decrease of 52% and after three minutes of rest. HR increased 67 bpm during exertion and decreased by 75 bpm at the third minute of rest. Discussion: According to existing data the increase of Hb in young TM ranges from 4.9% to 12.5% and Ht from 4.4% to 17.6%, whereas in our case it varied 23% and 27%, respectively. The average HDLc drop between 3 and 24 months of T use is, respectively, -6,5 and -8,5 mg/dL, less than what is found in this report (-13 mg/dL). Cis women’s BMD decreases around 2% in lumbar spine, 1,4% in total hip and the MM shows reduction of 1lb 5,2oz during first year of climateric. Young cis women and men present an increase in SBP during ET around 34.0% and 39.8%, respectively, and in the third minute of recovery a drop around 20.6% and 23.4%. HR drops from 60.5 to 64.53 bpm in the third minute of rest and higher recoveries are associated with better parasympathetic reactivation and lower mortality. Conclusion: TM over 50 yo seems to present higher increase of Hb/HT and decrease of HDLc when compared to younger TM. The ET findings after 1 year of T might be a consequence of enlarged cardiac chambers, increased systolic volume and peripheral vascular resistance. TM who start T over 50 yo may need more careful CV screening.
format Online
Article
Text
id pubmed-7208401
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72084012020-05-13 SUN-053 Evaluation of a 52-Year-Old Transgender Man During the First Year of Testosterone Therapy - Biochemical Changes, Body Composition and Cardiovascular Aspects at the Ergometric Test: A Case Report Alvares, Leonardo Azevedo Mobilia Nakamoto, Fernanda Patti Pimenta, Isabella Ferreira Netto, Luiza Travassos da Rosa Ramos, Henrique Afonso boas, Roberta Frota Villas Bueno, Thiago Limoli Santos, Lívia Marcela Silva, Frank Mobilia Alvares J Endocr Soc Reproductive Endocrinology Introduction: Testosterone (T) therapy is able to promote biochemical, body composition and cardiovascular (CV) changes in transgender men (TM). However, existing data concerns TM between 18 and 50 years old. Objective: To describe the first year of T therapy in a 52 yo TM - biochemical changes, body composition and CV aspects during exercise. Methods: Medical record review was accessed as well as laboratorial and image exams performed during the first year of T use. Results: TM, 52 yo, in perimenopause, normal weight, without chronic diseases, no previous usage of T, initiated testosterone undecanoate 1.000mg. A second dose was given 6 weeks after the first one and then every 12 weeks. Lab exams were collected on the day before the next shot of T. By the third month of treatment, it has been noted the highest level of T (586 ng/dL). Initial hemoglobin (Hb) was 13.0 g/dL and hematocrit (Ht) 37.1%. After 7 months of treatment they reached their highest levels, 16.3 g/dL (23%) and 47,1% (27%). LDLc increased from 106 to 139 mg/dL (31%) by the seventh month. HDLc dropped from 73 to 60 (- 13 mg/dL) by the seventh month. Initial bone mineral density (BMD) was normal and increased 3.1% in lumbar spine (L1-L4) and 2.7% in femoral neck after 1 year. The muscle mass (MM) increased 10.9% in one year. The ergometric test (ET) at the beginning of treatment showed an increase in systolic blood pressure (SBP) of 38.4% (130 to 180 mmHg) during exertion and a decrease of 27.7% in the third minute of passive recovery; as well as an increase in Heart Rate (HR) of 73 bpm during exertion and a reduction of 72 bpm at third minute of rest. One year after the use of T, SBP increased by 61.5% (130 to 210 mmHg), with a decrease of 52% and after three minutes of rest. HR increased 67 bpm during exertion and decreased by 75 bpm at the third minute of rest. Discussion: According to existing data the increase of Hb in young TM ranges from 4.9% to 12.5% and Ht from 4.4% to 17.6%, whereas in our case it varied 23% and 27%, respectively. The average HDLc drop between 3 and 24 months of T use is, respectively, -6,5 and -8,5 mg/dL, less than what is found in this report (-13 mg/dL). Cis women’s BMD decreases around 2% in lumbar spine, 1,4% in total hip and the MM shows reduction of 1lb 5,2oz during first year of climateric. Young cis women and men present an increase in SBP during ET around 34.0% and 39.8%, respectively, and in the third minute of recovery a drop around 20.6% and 23.4%. HR drops from 60.5 to 64.53 bpm in the third minute of rest and higher recoveries are associated with better parasympathetic reactivation and lower mortality. Conclusion: TM over 50 yo seems to present higher increase of Hb/HT and decrease of HDLc when compared to younger TM. The ET findings after 1 year of T might be a consequence of enlarged cardiac chambers, increased systolic volume and peripheral vascular resistance. TM who start T over 50 yo may need more careful CV screening. Oxford University Press 2020-05-08 /pmc/articles/PMC7208401/ http://dx.doi.org/10.1210/jendso/bvaa046.903 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reproductive Endocrinology
Alvares, Leonardo Azevedo Mobilia
Nakamoto, Fernanda Patti
Pimenta, Isabella Ferreira
Netto, Luiza Travassos da Rosa
Ramos, Henrique Afonso
boas, Roberta Frota Villas
Bueno, Thiago Limoli
Santos, Lívia Marcela
Silva, Frank Mobilia Alvares
SUN-053 Evaluation of a 52-Year-Old Transgender Man During the First Year of Testosterone Therapy - Biochemical Changes, Body Composition and Cardiovascular Aspects at the Ergometric Test: A Case Report
title SUN-053 Evaluation of a 52-Year-Old Transgender Man During the First Year of Testosterone Therapy - Biochemical Changes, Body Composition and Cardiovascular Aspects at the Ergometric Test: A Case Report
title_full SUN-053 Evaluation of a 52-Year-Old Transgender Man During the First Year of Testosterone Therapy - Biochemical Changes, Body Composition and Cardiovascular Aspects at the Ergometric Test: A Case Report
title_fullStr SUN-053 Evaluation of a 52-Year-Old Transgender Man During the First Year of Testosterone Therapy - Biochemical Changes, Body Composition and Cardiovascular Aspects at the Ergometric Test: A Case Report
title_full_unstemmed SUN-053 Evaluation of a 52-Year-Old Transgender Man During the First Year of Testosterone Therapy - Biochemical Changes, Body Composition and Cardiovascular Aspects at the Ergometric Test: A Case Report
title_short SUN-053 Evaluation of a 52-Year-Old Transgender Man During the First Year of Testosterone Therapy - Biochemical Changes, Body Composition and Cardiovascular Aspects at the Ergometric Test: A Case Report
title_sort sun-053 evaluation of a 52-year-old transgender man during the first year of testosterone therapy - biochemical changes, body composition and cardiovascular aspects at the ergometric test: a case report
topic Reproductive Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208401/
http://dx.doi.org/10.1210/jendso/bvaa046.903
work_keys_str_mv AT alvaresleonardoazevedomobilia sun053evaluationofa52yearoldtransgendermanduringthefirstyearoftestosteronetherapybiochemicalchangesbodycompositionandcardiovascularaspectsattheergometrictestacasereport
AT nakamotofernandapatti sun053evaluationofa52yearoldtransgendermanduringthefirstyearoftestosteronetherapybiochemicalchangesbodycompositionandcardiovascularaspectsattheergometrictestacasereport
AT pimentaisabellaferreira sun053evaluationofa52yearoldtransgendermanduringthefirstyearoftestosteronetherapybiochemicalchangesbodycompositionandcardiovascularaspectsattheergometrictestacasereport
AT nettoluizatravassosdarosa sun053evaluationofa52yearoldtransgendermanduringthefirstyearoftestosteronetherapybiochemicalchangesbodycompositionandcardiovascularaspectsattheergometrictestacasereport
AT ramoshenriqueafonso sun053evaluationofa52yearoldtransgendermanduringthefirstyearoftestosteronetherapybiochemicalchangesbodycompositionandcardiovascularaspectsattheergometrictestacasereport
AT boasrobertafrotavillas sun053evaluationofa52yearoldtransgendermanduringthefirstyearoftestosteronetherapybiochemicalchangesbodycompositionandcardiovascularaspectsattheergometrictestacasereport
AT buenothiagolimoli sun053evaluationofa52yearoldtransgendermanduringthefirstyearoftestosteronetherapybiochemicalchangesbodycompositionandcardiovascularaspectsattheergometrictestacasereport
AT santosliviamarcela sun053evaluationofa52yearoldtransgendermanduringthefirstyearoftestosteronetherapybiochemicalchangesbodycompositionandcardiovascularaspectsattheergometrictestacasereport
AT silvafrankmobiliaalvares sun053evaluationofa52yearoldtransgendermanduringthefirstyearoftestosteronetherapybiochemicalchangesbodycompositionandcardiovascularaspectsattheergometrictestacasereport